Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Mitomycin-C for prevention of corneal haze after myopic photorefractive keratectomy: a comparison between 1% and 2% concentrations

Poster Details

First Author: H.Razmjoo IRAN

Co Author(s):    A. Peyman   M. Kooshanmehr           

Abstract Details


to compare effectiveness of Mitomycin-C with two different concentrations of 1% and 2% for prevention of corneal haziness after myopic photorefractive keratectomy (PRK)


Isfahan Eye Research Center, Isfahan University of Medical Sciences


85 patients enrolled in this prospective study. In each subject one eye randomly assigned to group 1 and the second eye to the group 2. Patients underwent surface ablation for treatment of myopia and myopic astigmatism with tissue saving protocol of a Technolas 217z excimer system. In both groups alcohol used for epithelial removal and similar post-op antibiotic and corticosteroid drops prescribed. In group 1 after ablation Mitomycin-C 1% (0.1mg/ml) solution applied to cornea for 30 seconds, and in group 2 we used Mitomycin-C with concentration of 2% (0.2mg/ml) for 30 seconds before irrigation of the surface and placement of bandage lens.


at 1 month post-operative visits 8.2% of patients in group 1 had grade 2 corneal haze compared to 4.7% in group 2. In months 2, 3, and 6 visits 7.1%, 0%, 0% patients in group 1, and 3.5%, 0%, 0% patients in group 2 had grade 2 of cornea haziness, respectively. No patients in each group had grade 3 or more score of haziness in every group. Although patients seemed to have marginally less corneal haze with 2% concentration of Mitomycin-C the difference between groups was not statistically significant (P>0.05 for all comparisons).


There is no difference between 1% and 2% concentrations of Mitomycin-C regarding prevention of corneal haze formation after myopic photorefractive keratectomy. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.